The primary objectives were:
- To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra®
(Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of
patients achieving target glycemic control (as measured by hemoglobin A1c [HbA1c] <7.0%)
at Week 60
- To demonstrate the noninferiority of Lantus plus addition of 1 mealtime Apidra injection
(Lantus/Apidra-1) versus twice-daily Premixed insulin based on the reduction from
Baseline to Week 60 in HbA1c